FBT ETF Analysis: NYSE Arca Biotechnology | NYSE
Healthcare Equity | NYSE, USA | Market Cap: 3.104m USD | 12M Return: 38.2% | US33733E2037 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.7M
Warnings
No concerns identified
Tailwinds
Seasonality 11.8 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
The First Trust NYSE Arca Biotechnology Index Fund (FBT) is a U.S.-listed exchange-traded fund that seeks to track the performance of the NYSE Arca Biotechnology Index, an equal-dollar weighted benchmark composed of 30 leading biotechnology companies. To maintain this focus, the fund commits at least 90% of its net assets to the securities held in the index.
Biotechnology companies develop therapies, vaccines, diagnostics, and platform technologies based on biological processes, often targeting areas such as oncology, rare diseases, and genetic disorders. Equal-dollar weighting differentiates the index from market-cap-weighted benchmarks by assigning each constituent the same dollar allocation at rebalancing, giving smaller biotech firms a larger relative footprint than they would receive in a cap-weighted approach.
- FDA drug approval decisions drive index constituent performance
- Biotech M&A activity lifts valuations across index holdings
- Drug pricing reform legislation threatens sector revenue and margins
As of November 11, 2026, the stock is trading at USD 271.59 with a total of 39,254 shares traded. Over the past week, the price has changed by -1.63%, over one month by +2.91%, over three months by +5.05% and over the past year by +38.22%.
Current recommended Stop Loss: 262.90 (which is 3.2% or 1.4 ATR below the current price).
NYSE Arca Biotechnology has no consensus analysts rating.